| Literature DB >> 16803568 |
Francis Giles1, Srdan Verstovsek, Guillermo Garcia-Manero, Deborah Thomas, Farhad Ravandi, William Wierda, Alessandra Ferrajoli, Steve Kornblau, Elias Jabbour, Jianqin Shan, Susan O'brien, Maher Albitar, Hagop Kantarjian.
Abstract
In order to validate the European Prognostic Index (EPI) for patients <or=60 years with acute myeloid leukaemia in first relapse, a cohort of 599 such patients, treated between 1980 and 2004 at the MD Anderson Cancer Center, were assessed using this prognostic index. Three risk groups were defined: favourable, 76 patients (13%) [Overall survival (OS), 64% at 1 year, 22% at 5 years]; intermediate, 137 patients (23%) (OS, 38% at 1 year, 12% at 5 years); and poor, 386 patients (64%) (OS, 17% at 1 year 6% at 5 years). The EPI is reproducible and useful.Entities:
Mesh：
Year: 2006 PMID： 16803568 DOI： 10.1111/j.1365-2141.2006.06106.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998